Skip to content

AgomAb Therapeutics

Active
Public limited companyfounded 2017active for 9 yearsPosthoflei 1, 2600 Antwerpen, Belgium10 active companies are registered at this addressKBO/BCE: BE 0674.527.310

From the official registers: KBO 9 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

AgomAb Therapeutics has been active since 2017 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €244.1m and a net result of -€9.6m. Equity is growing by about 109% per year across the filed financial years. Its solvency ranks better than 95% of 892 sector peers (NACE 71, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).

Risk analysisFollow ReportCompare
AgomAb TherapeuticsActiveChecked score 95/100
Risk analysis ReportCompare

Directors

Directors
9 directors, 1 in day-to-day management, no change since 2026

Board 9

David Epstein
Voorzitter bestuurder · appointed in the act of 18-07-2024 · in the 2025 annual accounts, filed on 23-06-2026
Current
HAMMER Ohad
Director · appointed in the act of 09-04-2019
Current
KNOTNERUS Tim Jasper
Director · since 05-03-2021 · in the 2025 annual accounts, filed on 23-06-2026
Current
Tim Knotnerus
Director · since 05-03-2021 · in the 2025 annual accounts, filed on 23-06-2026
Current
Angelika Martha Jahreis
Independent director · since 10-10-2023 · in the 2025 annual accounts, filed on 23-06-2026
Current
Verduyn - van Weegen Felice
Director · since 10-10-2023 · in the 2025 annual accounts, filed on 23-06-2026
Current
Colin Michael BOND
Independent director · since 15-11-2024 · in the 2025 annual accounts, filed on 23-06-2026
Current
Marino Garcia
Non-executive director · appointed in the act of 12-10-2026
Current
Show all 9 directors
Naimish Patel
Non-executive director · appointed in the act of 12-10-2026
Current

Day-to-day management 1

KNOTNERUS Tim Jasper
Ceo bestuurder · appointed in the act of 18-03-2021
Current

Statutory auditor 1

BV PwC Bedrijfsrevisoren
Statutory auditor · since 28-05-2024 · permanent representative: Didier Delanoye · in the 2025 annual accounts, filed on 23-06-2026
Current
Office holders in the KBO →

Mandate history

22 people, 10 in office
Show
  • Board
  • Day-to-day management
  • Statutory auditor
  • began earlier
  • end not dated
Mandates per person, with start and end dates
Name Functions and periods
KNOTNERUS Tim Jasper
  • Manager, appointed in the act of 14-03-2018, until 09-04-2019
  • Director, since before 09-04-2019
  • Ceo bestuurder, appointed in the act of 18-03-2021, still in office
HAMMER Ohad
  • Director, appointed in the act of 09-04-2019, still in office
Tim Knotnerus
  • Day-to-day manager, appointed in the act of 03-10-2019, last mentioned in 2019
  • Director, since before 19-06-2026
Angelika Martha Jahreis
  • Independent director, from 10-10-2023 to date
Verduyn - van Weegen Felice
  • Director, from 10-10-2023 to date
David Epstein
  • Voorzitter bestuurder, from 08-07-2024 to date
Colin Michael BOND
  • Independent director, from 15-11-2024 to date
Marino Garcia
  • Non-executive director, appointed in the act of 12-10-2026, still in office
Naimish Patel
  • Non-executive director, appointed in the act of 12-10-2026, still in office
BV PwC Bedrijfsrevisoren
  • Statutory auditor, appointed in the act of 25-11-2021, still in office
Xiaoming Fang
  • Klasse b investeerder bestuurder, appointed in the act of 18-10-2023, until 16-01-2026
HAURUM John, Sørensen
  • Director, appointed in the act of 09-04-2019, no longer listed in the 2025 annual accounts
  • Voorzitter bestuurder, until 08-07-2024
Felice Isabel van Weegen
  • Klasse c investeerder bestuurder, appointed in the act of 18-10-2023, no longer listed in the 2025 annual accounts
LEE Michael Stewart
  • Klasse b investeerder bestuurder, appointed in the act of 18-03-2021, until 10-10-2023
BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISES
  • Statutory auditor, appointed in the act of 09-04-2019, until 29-10-2021
MICHIELI Paolo
  • Manager, appointed in the act of 18-04-2017, until 09-04-2019
  • Director, from before 09-04-2019 to 21-05-2021
COUTET Matthieu, Philippe, Christian
  • Manager, appointed in the act of 12-11-2018, until 09-04-2019
  • Director, from before 09-04-2019 to 05-03-2021
POULARD Claire
  • Director, appointed in the act of 09-04-2019, until 05-03-2021
ROZENKRANZ Katja
  • Manager, appointed in the act of 14-03-2018, until 09-04-2019
  • Director, from before 09-04-2019 to 05-03-2021
ZANZINGER Johannes, Friedrich
  • Director, appointed in the act of 01-07-2019, until 05-03-2021
WICKE Ilka
  • Director, appointed in the act of 09-04-2019, until 27-06-2019
TAKKE Christina
  • Manager, appointed in the act of 14-03-2018, until 19-10-2018
See the board, name and registered office on a given date →

How the board is organised

Who represents it, and how

Who signsWho may bind the company towards others, for example by signing a contract.
“Artikel 41. VERTEGENWOORDIGINGSBEVOEGDHEID. 41.1. De raad van bestuur vertegenwoordigt de Vennootschap als orgaan, zowel in als buiten…”
deed of 26-02-2026
Board ruleHow the board is made up, meets and takes decisions.
“Alle handelingen nodig of dienstig voor verwezenlijking van het voorwerp, bevoegdheden raad van bestuur”
“Samenstelling raad van bestuur, bestuurders al dan niet aandeelhouders”
“De raad van bestuur is bevoegd om alle handelingen te verrichten, die nodig of dienstig zijn voor de verwezenlijking van het voorwerp van de…”
“De duur van hun opdracht mag zes (6) jaar niet te boven gaan. De opdrachten eindigen onmiddellijk na de gewone algemene vergadering in het…”
1 more provision on this in the deed
deed of 26-02-2026 (in Dutch)
Power of attorneyA special mandate allowing someone to perform one or more acts on the company's behalf.
One provision in the deed
deed of 12-10-2026 (in Dutch)

Oversight and winding up

Dissolution ruleWhen and by whom the company can be dissolved.
“Ontbinding, te allen tijde”
1 more provision on this in the deed
Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
“Ontbinding en vereffening, algemene aandeelhoudersvergadering verleent kwijting van aansprakelijkheid”
1 more provision on this in the deed

deed of 26-02-2026 (in Dutch)

Owners and capital

Owners

4 owners

Owners 4

Former owners (1)

Capital and shareholders

Shareholders according to the deeds
Share transfer act of 26-10-2026 ↗
  • from AgomAb Therapeutics 210,170 shares
Stated in the act act of 26-02-2026 ↗
  • The Bank of New York Mellon bewaarinstelling (depositary financial institution) · 12,500,000 shares
Share transfer act of 26-02-2026 ↗
  • shares transferred 342,206 shares
  • shares transferred 455,004 shares
  • shares transferred 479,040 shares
  • shares transferred 277,272 shares
  • shares transferred
At incorporation act of 09-04-2019 ↗
Share transfer act of 14-03-2018 ↗
At incorporation act of 18-04-2017 ↗
  • EUREMAB SRL 2,500 shares
  • MICHIELI Paolo 13,500 shares
  • DE HAARD ANTIBODY TECHNOLOGIES B.V. 3,000 shares
  • SAUNDERS Michael John Scott 3,000 shares
  • MORELLO Virginia 1,250 shares
  • CAZZANTI Manuela 1,250 shares
  • LINTY Federica Caterina 500 shares
Capital over the years
  1. 26-10-2026 Capital increase of €229,347.31 · to €303,287,161.22 · 210,170 new shares · inschrijvingsrechten
  2. 17-04-2026 Capital increase of €64,467.19 · to €303,057,813.91 · 28,229 new shares · in cash
  3. 08-04-2026 Capital increase · 482,967 new shares · in cash
  4. 08-04-2026 Capital increase of €2,973,096.56 · 482,967 new shares · in cash
  5. 26-02-2026 Capital increase · 12,500,000 new shares
  6. 26-02-2026 Capital increase · 12,500,000 new shares · in cash
  7. 19-11-2024 Capital increase of €48,359,418.36 · to €223,071,500.16 · 342,206 new shares · in cash
  8. 18-10-2023 Capital increase of €64,299,658.07 · to €174,712,081.80 · 455,004 new shares · in cash
Show 20 older capital entries
  1. 15-07-2022 Capital increase of €26,014,423.73 · to €110,412,423.73 · 184,086 new shares
  2. 09-11-2021 Capital increase of €1,720,000 · to €84,398,000 · 8,249 new shares
  3. 18-03-2021 Capital increase of €59,780,000 · to €82,678,000 · 286,705 new shares
  4. 25-11-2020 Capital increase of €6,144,381.12 · to €21,521,638.64 · 86,298 new shares
  5. 25-11-2020 Capital increase of €1,376,361.36 · to €22,898,000 · no new shares · “omzetting in het kapitaal van de bedragen afgenomen van de rekening "Uitgiftepremies"”
  6. 31-07-2020 Capital increase of €957,349.52 · to €15,377,257.52 · 13,446 new shares
  7. 27-04-2020 Capital increase of €3,326,795.90 · to €13,507,126.90 · 49,877 new shares
  8. 27-04-2020 Capital increase of €912,781.10 · to €14,419,908 · no new shares · “omzetting van uitgiftepremies”
  9. 14-10-2019 Capital increase of €3,439,856.98 · to €8,131,433.98 · 64,574 new shares
  10. 14-10-2019 Capital increase of €2,048,897.02 · to €10,180,331 · no new shares · omzetting uitgiftepremies
  11. 01-07-2019 Capital increase of €30,297.26 · to €4,673,297.26 · 571 new shares · in cash
  12. 01-07-2019 Capital increase of €18,279.74 · to €4,691,577 · no new shares · “omzetting van uitgiftepremies in kapitaal”
  13. 09-04-2019 Capital increase of €748,190.40 · to €1,391,190.40 · 47,056 new shares · in cash
  14. 09-04-2019 Capital increase of €3,251,809.60 · conversion_of_Uitgiftepremies_into_capital
  15. 09-04-2019 Capital increase of €748,190.40 · 47,056 new shares
  16. 09-04-2019 Capital increase of €3,251,809.60 · to €4,643,000 · no new shares · “omzetting in het kapitaal van bedrag afgenomen van rekening Uitgiftepremies”
  17. 12-11-2018 Capital increase of €200,000 · to €643,000 · 5,000 new shares
  18. 14-03-2018 Capital increase of €110,000 · to €135,000 · 2,750 new shares
  19. 14-03-2018 Capital increase of €308,000 · to €443,000 · 7,700 new shares
  20. 18-04-2017 Incorporation · €25,000 · 25,000 shares

Shares according to the articles of association

Capital, shares and profit

Kind of sharesWhich classes of shares exist and what rights each class carries.
“Klassen van aandelen, 8”
deed of 09-04-2019 (in Dutch)
Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
“11”
“11, aandelenoverdracht bij uitoefening koopoptie overeenkomstig Overeenkomst”
1 more provision on this in the deed
deed of 09-04-2019 (in Dutch)
Authorised capitalThe amount by which the board may raise capital without a new shareholder decision.
“Vervanging en hernieuwing, EUR”
deed of 08-04-2026 (in Dutch)
Financial instrumentSecurities other than shares, such as bonds or warrants, the company can issue.
“Employee Stock Optie Warrants, gewone aandelen”
“2022 Employee Stock Optie Warrants, gewone aandelen”
“2023 Employee Stock Optie Warrants, gewone aandelen”
“2024 Employee Stock Optie Warrants, gewone aandelen”
deed of 17-04-2026 (in Dutch)
Profit allocationHow profit is distributed; a BV may only pay out after a balance-sheet and liquidity test.
One provision in the deed
deed of 26-02-2026 (in Dutch)

Other provisionsRules from the articles on subjects other than the board, the shares, the purpose and the meetings.

1 more provision in the deed, see the deed of 08-04-2026
“De IPO Kapitaalverhoging kan worden voltooid voor alle of een deel van de inschrijvingen in één of meerdere transacties via opeenvolgende…”
“Indien niet op alle aangeboden aandelen wordt ingeschreven, kan de verhoging toch worden voltooid voor alle of een deel van de aanvaardde…”
“Zelfs indien op alle aangeboden aandelen wordt ingeschreven, kan de verhoging worden voltooid door minder aandelen uit te geven dan het…”
“De raad van bestuur of het IPO Comité kan besluiten om de beoogde IPO Kapitaalverhoging niet door te voeren, zelfs indien op alle of een…”
“De IPO Kapitaalverhoging en BAV Besluiten kunnen plaatsvinden voor zover (i) de verhoging kwalificeert als een 'Kwalificerende IPO' volgens…”
2 more provisions in the deed, see the deed of 26-02-2026
deed of 26-02-2026 (in Dutch)
2 more provisions in the deed, see the deed of 09-04-2019

We would like to set cookies. That happens only with your consent. What we measure